Novo Nordisk Invests €432M in Athlone Facility Expansion

Key highlights
  • Novo Nordisk invests €432 million in Athlone, Ireland facility.
  • The expansion focuses on GLP-1 oral treatments.
  • 500 construction jobs will be created.
  • Completion is expected between 2027 and 2028.
Related project For subscribers
Milestones, plant data, involved companies (owners, investors, licensors, contractors) and news — kept up to date.
Novo Nordisk Athlone (Monksland) oral GLP-1 tabletting expansion · Ireland
Under Construction
2025
2026-03-02
2026 Q1
—
Operational / Completed · expected date for subscribers

Investment Overview

Novo Nordisk has announced a €432 million investment in its Monksland facility in Athlone, Ireland. This expansion aims to increase manufacturing capacity for GLP-1 oral treatments.

Strategic Importance

The investment enhances Novo Nordisk's manufacturing capabilities for oral products and strengthens Ireland's role as a key hub for servicing markets outside the US. The project will upgrade and retrofit the existing facility.

Job Creation and Timeline

The expansion will create up to 500 construction jobs. The construction projects have already begun and are expected to be completed gradually from the end of 2027 through 2028.

Current Operations

The existing 260 employees at the Athlone plant will focus on delivering high-quality oral treatments efficiently and sustainably.

Source: Novo Nordisk

chemXplore Weekly

The week’s project milestones and project news from the chemical industry, free every Wednesday.

Free. One email a week. Unsubscribe any time. See our Privacy Policy.

Related articles

16 November 2026
Novo reports early bone-protection signals from amylin and calcitonin receptor agonists

Findings span an ovariectomized-rat model, small human biomarker studies and exploratory analyses from the 68-week REDEFINE 1 trial.

1 October 2026
Novo Nordisk: Wegovy normalised liver fat in 88.5% of obese adults in STEP UP subanalysis

MRI‑PDFF subanalysis (n=55) found mean liver fat fell from 8.8% to 3.1% at week 72; 88.5% with baseline liver fat >5% reached <5%.

5 June 2026
Novo Nordisk zenagamtide (amycretin) delivers large HbA1c and weight reductions in phase 2 T2D trial

Unimolecular GLP‑1/amylin agonist produced substantial HbA1c and weight reductions in a 36‑week phase 2 trial in adults with type 2 diabetes on metformin ± SGLT2i.

25 February 2026
Novo Nordisk and Vivtex Collaborate on Oral Medicines for Obesity and Diabetes

The partnership aims to develop oral biologics for obesity and diabetes, leveraging Vivtex's technology for better bioavailability and Novo Nordisk's expertise in global development and commercialization.

24 February 2026
Novo Nordisk's UBT251 Achieves 19.7% Weight Loss in Phase 2 China Trial

UBT251, a triple agonist, showed significant weight loss and improved health markers in a Chinese phase 2 trial, with a safe and well-tolerated profile.